<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39413503</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9157</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of autoimmunity</Title><ISOAbbreviation>J Autoimmun</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 mRNA vaccines do not worsen autoimmunity in patients with autoimmune liver diseases.</ArticleTitle><Pagination><StartPage>103325</StartPage><MedlinePgn>103325</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaut.2024.103325</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-8411(24)00159-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND AIMS" NlmCategory="OBJECTIVE">mRNA vaccines against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) infection have been associated with immune-related adverse reactions. We aimed at investigating whether SARS-CoV-2 vaccines may worsen autoimmune reactions in patients with autoimmune liver diseases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We centrally tested a large panel of liver- and non-liver-related autoantibodies in patients with primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), and in healthcare workers (HW) before and after SARS-CoV-2 mRNA vaccines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">49 PBC, 35 AIH, 9 PSC and 38 HW were included. The proportion of subjects with at least one autoantibody positivization after vaccination was 11 % for HW, 37 % for AIH, 35 % for PBC and 56 % for PSC patients, patients having a significantly higher frequency of positivization as compared to HW. The proportion of seropositive subjects before vaccination who had at least one autoantibody negativization was 25 % for HW, 57 % for AIH, 40 % for PBC and 50 % for PSC, AIH patients having a significantly higher frequency of negativization as compared to HW. In the AIH group, the number of autoantibody negativizations was higher than the number of positivizations. The BNT162b2 vaccine was associated with a higher risk of developing new autoantibodies as compared to the mRNA-1273 vaccine. No new-onset autoimmune disease was observed after one year. One AIH patient had a relapse after vaccination.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">mRNA SARS-CoV-2 vaccines do not induce short-term worsening of autoimmunity in patients with autoimmune liver diseases.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kälin</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passarin</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Independent biostatistician, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filipowic-Sinnreich</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinic for Gastroenterology and Hepatology, Medizinische Universitätsklinik, Kantonsspital Baselland, Liestal, Switzerland; Department of Biomedicine, University of Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semela</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology Department, Kantonsspital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seifert</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika AG, Seekamp 31, 23560, Luebeck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallusto</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland; Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland; Institute of Microbiology, ETH Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergani</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>MowatLabs, Faculty of Life Sciences &amp; Medicine, King's College London, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerny</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epatocentro Ticino, Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mieli-Vergani</LastName><ForeName>Giorgina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MowatLabs, Faculty of Life Sciences &amp; Medicine, King's College London, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terziroli Beretta-Piccoli</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland; Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland; MowatLabs, Faculty of Life Sciences &amp; Medicine, King's College London, King's College Hospital, London, UK; Epatocentro Ticino, Lugano, Switzerland. Electronic address: benedetta.terziroli@usi.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Swiss Autoimmune Hepatitis Cohort Study</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Swiss Primary Biliary Cholangitis Cohort Study</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Swiss Primary Sclerosing Cholangitis Study</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Autoimmun</MedlineTA><NlmUniqueID>8812164</NlmUniqueID><ISSNLinking>0896-8411</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune liver diseases</Keyword><Keyword MajorTopicYN="N">Liver autoantibodies</Keyword><Keyword MajorTopicYN="N">mRNA SARS-CoV-2 vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39413503</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2024.103325</ArticleId><ArticleId IdType="pii">S0896-8411(24)00159-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>